Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: HIV-1-infection

In brief

For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body and can start multiplying when ART is stopped. This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance that the body makes in response to an infection. The antibodies being used in this study were made in a laboratory and were designed to attach to HIV and can block HIV from attacking cells in the body and from spreading to other parts of the body. These antibodies are being developed to potentially treat and prevent HIV. The main purpose of this study is to see if the study drugs affect the level of HIV that remains in the blood cells while taking ART and the level of HIV in the blood after discontinuing taking ART. The study will also see if it is safe to give people these antibodies and if they cause any side effects.

Key facts

Study ID
NCT06205602
Run by
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
People needed
135
Starts
2025-01-17
Expected to finish
2029-02-16
Last updated by the study team
2025-01-31

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.